Compare Abeona Therapeutics Inc (ABEO) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares Ultra Bitcoin ETF — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while ProShares Ultra Bitcoin ETF trades at $8.89. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | BITU | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $64.41 |
52-Week Low | $4.17 | $8.12 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BITU trades at $9.48, up 7.36% in the last 24 hours, with a bullish technical signal but bearish moving averages. The stock faces structural challenges as a leveraged ETF, with key financial ratios like P/E and P/S unavailable. Recent news highlights underperformance relative to Bitcoin due to daily rebalancing decay, with Seeking Alpha rating it a Hold on June 16, 2026.
Outlook remains cautious due to BITU's leveraged structure and volatility decay risks. Investment opportunities are limited to short-term tactical plays during clear bull markets, but long-term holders face significant erosion. Primary risks include ETF mechanics, Bitcoin price dependency, and investor sentiment shifts amid crypto volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
